Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant SARS-CoV-2 Spike antibody (Receptor Binding Domain) (Fc Tag)

This anti-SARS-CoV-2 Spike antibody is a Human Monoclonal antibody detecting SARS-CoV-2 Spike in ELISA, Neut and GICA. Suitable for SARS Coronavirus-2 (SARS-CoV-2).
Catalog No. ABIN6953152

Quick Overview for Recombinant SARS-CoV-2 Spike antibody (Receptor Binding Domain) (Fc Tag) (ABIN6953152)

Target

See all SARS-CoV-2 Spike Antibodies
SARS-CoV-2 Spike

Antibody Type

Recombinant Antibody

Fragment

single-domain Antibody (sdAb)

Reactivity

  • 94
  • 7
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
SARS Coronavirus-2 (SARS-CoV-2)

Host

  • 35
  • 32
  • 21
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
Human

Clonality

  • 64
  • 18
  • 13
Monoclonal

Conjugate

  • 78
  • 8
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This SARS-CoV-2 Spike antibody is conjugated to Fc Tag

Application

  • 74
  • 32
  • 27
  • 10
  • 10
  • 7
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
ELISA, Neutralization (Neut), Colloidal Gold Immunochromatography Assay (GICA)

Clone

A1
  • Binding Specificity

    • 52
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 319-541, Receptor Binding Domain

    Purpose

    SARS-CoV-2 Spike RBD single-domain Antidbody

    Characteristics

    This SARS-CoV-2 Spike RBD Nanobody is a recombinant monoclonal antibody generated through the expression of a DNA sequence inserting a human IgG1 Fc domain at the C-terminus, in human embryonic kidney 293 cells (HEK293). The DNA sequence encodes the SARS-CoV-2 spike receptor-binding domain (RBD). The antibody is purified by protein G in vitro. It has been validated with high reactivity towards SARS-CoV-2-S1-RBD by a functional ELISA and good sensitivity for human SARS-CoV-2 spike glycoprotein (S protein) via the Colloidal Gold Immunochromatography Assay (GICA). In neutralization assay, the binding signal of SARS-CoV-2 Spike RBD Nanobody was inhibited by ACE2 protein-HRP conjugated inhibitor, with a 0.1074 μg/mL IC50. Specifically binding and recognizing the RBD of the SARS-CoV-2 spike glycoprotein (S protein), so the SARS-CoV-2 Spike RBD Nanobody can react with samples infected with human coronavirus SARS-CoV-2. But it does not respond to MERS or SARS-CoV spike protein. Akin to other nanobodies, this recombinant nanobody is small and stable, which allows for its reaching to hidden epitopes such as crevices of target proteins.
    VHH fusion with human IgG1 Fc

    Purification

    Affinity-chromatography

    Immunogen

    Recombinant Human Novel Coronavirus Spike glycoprotein(S) (319-541aa) (CSB-YP3324GMY1 and CSB-MP3324GMY1b1)

    Isotype

    IgG1
  • Application Notes

    ELISA:1:10000-1:100000, GICA:1:10000-1:40000, Neutralising:1:100-1:10000

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Preservative: 0.03 % Proclin 300
    Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

    Preservative

    ProClin

    Precaution of Use

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    -20 °C,-80 °C

    Storage Comment

    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze
  • Target

    SARS-CoV-2 Spike

    Alternative Name

    SARS-CoV-2 (SARS-CoV-2/ 2019-nCoV) SARS-CoV-2 Spike

    Background

    Spike glycoprotein comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and fusion of the viral and cellular membranes (S2 subunit). For many coronavirus (CoVs), S is cleaved at the boundary between the S1 and S2 subunits, which remain non-covalently bound in the prefusion conformation. The distal S1 subunit comprises the receptor-binding domain(s) and contributes to stabilization of the prefusion state of the membrane-anchored S2 subunit that contains the fusion machinery. S is further cleaved by host proteases at the so-called S2' site located immediately upstream of the fusion peptide in all CoVs. This cleavage has been proposed to activate the protein for membrane fusion via extensive irreversible conformational changes. However, different CoVs use distinct domains within the S1 subunit to recognize a variety of attachment and entry receptors, depending on the viral species. Endemic human coronaviruses OC43 and HKU1 attach via their S domain A to 5-N-acetyl-9-O-acetyl-sialosides found on glycoproteins and glycolipids at the host cell surface to enable entry into susceptible cells. MERS-CoV S uses domain A to recognize non-acetylated sialoside attachment receptors, which likely promote subsequent binding of domain B to the entry receptor, dipeptidyl-peptidase 4. SARS-CoV and several SARS-related coronaviruses (SARSr-CoV) interact directly with angiotensin-converting enzyme 2 (ACE2) via SB to enter target cells.

    Gene ID

    43740568

    UniProt

    P0DTC2
You are here:
Chat with us!